Chinese herbal feed additive for preventing enteritis of animals and its preparation method

Abstract

The application discloses a Chinese herbal medicine feed additive for preventing enteritis of animals and a preparation method thereof, and relates to the technical field of enteritis treatment of animals. It is found that the Trollius chinensis extract and the loganin both have the effect of treating enteritis, and the two are jointly used to prepare the feed additive, so that the level of inflammatory factors in the intestinal tract can be better reduced compared with the use of a single sample, and the synergistic effect of the two is verified. Meanwhile, due to the synergistic effect of the two substances, the Trollius chinensis extract and the loganin can be added into the feed when rabbits and other animals are bred, the survival rate of the rabbits is improved, the "green breeding and healthy breeding" of large-scale meat rabbit breeding enterprises is ensured, the disease incidence of the meat rabbits is reduced, and the benefits of the breeding enterprises are improved.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of animal enteritis treatment, more particularly to a Chinese herbal medicine feed additive for preventing animal enteritis and a preparation method thereof. BACKGROUND

[0002] Rabbit enteritis is harmful to rabbit breeding industry in China, especially weaned rabbits are prone to enteritis, which leads to increased mortality after diarrhea. Current treatment for enteritis relies on antibiotic therapy. With the implementation of the policy of banning and reducing antibiotics, Chinese herbal medicine is increasingly used due to its naturalness and no residue. Trollius chinensis, as a well-known Chinese herbal medicine, plays an important role in treating upper respiratory tract inflammation, but there is no report on treating enteritis.

[0003] Loganin is one of the most common iridoid glycosides, which is named after the first extraction of the compound from the plant of Strychnos, and is one of the main effective components in the fruit of the plant of Strychnos. It has the effect of enhancing non-specific immune function, promoting macrophage phagocytosis, and delaying aging. It has good anticancer and anti-radiation effects, and is widely used as a new type of anticancer drug in clinical medicine. It has good anti-inflammatory and antibacterial effects, and is commonly used as a raw material for traditional Chinese medicine. In addition, it has the effects of relieving cough and reducing sputum. Network pharmacology analysis shows that its current target is mainly the respiratory system, but given its certain anti-inflammatory effect, exploring whether it has the effect of treating enteritis has certain clinical significance for the research and development of enteritis drugs.

[0004] Therefore, how to apply Trollius chinensis and loganin in the treatment or prevention of animal enteritis is a technical problem that needs to be solved by those skilled in the art. SUMMARY

[0005] Therefore, the present application provides a Chinese herbal medicine feed additive for preventing animal enteritis and a preparation method thereof, which uses Trollius chinensis extract and loganin as main components, and the two components have a synergistic effect, which can significantly reduce intestinal inflammatory factors, achieve the purpose of treating enteritis, and overcome the defects in the prior art that Trollius chinensis extract and loganin cannot be applied to treat enteritis.

[0006] The first aspect of the present application provides the use of Trollius chinensis extract and loganin combination, the use includes any one of the following:

[0007] 1) use in the preparation of a drug for treating and / or preventing animal enteritis;

[0008] 2) use in the preparation of a feed additive for preventing animal enteritis;

[0009] The structure of the loganin is shown as formula I.

[0010] I

[0011] .

[0012] Compared with the prior art, the present application uses the combination of the extract of Potentilla Fritschii and the strychnine for treating or preventing enteritis of animals, because the inventors found that the extract of Potentilla Fritschii and the strychnine can both treat enteritis of animals when used alone, and the effect of treating enteritis is greatly improved after the combination of the two, which shows that the extract of Potentilla Fritschii and the strychnine have a synergistic effect, and lays a theoretical foundation for treating enteritis of animals in clinical animal medicine.

[0013] Further, the mass ratio of the extract of Potentilla Fritschii and the strychnine is (5-10): 1.

[0014] Compared with the prior art, the inventors found that the effect of treating enteritis is best when the mass ratio of the extract of Potentilla Fritschii and the strychnine is controlled at (5-10): 1.

[0015] Further, the combination of the extract of Potentilla Fritschii and the strychnine treats and / or prevents enteritis by any of the following ways:

[0016] 1) increasing the expression amount of Claudin-1, a tight junction protein of the intestinal tract;

[0017] 2) reducing the levels of TNF-α and IL-1β, two inflammatory factors of the jejunum and ileum.

[0018] Further, the preparation process of the extract of Potentilla Fritschii is as follows:

[0019] 1) washing the decocting pot and Potentilla Fritschii with clean water, and then soaking with water;

[0020] 2) adding water to the soaked Potentilla Fritschii, boiling with strong fire, and then adjusting to a weak fire;

[0021] 3) filtering, sterilizing, and repeatedly decocting twice to obtain the extract of Potentilla Fritschii.

[0022] Further, the soaking time with water in step 1) is 3h-5h;

[0023] Compared with the prior art, soaking Potentilla Fritschii with water can increase the effective components in the decocting liquid; when soaking for 3h-5h, the Potentilla Fritschii can be fully soaked with water, and the content of effective components can be maximized.

[0024] Further, in step 2), when adding water to the soaked Potentilla Fritschii, the water level should be 2-3cm higher than the surface of the medicinal material;

[0025] Further, the time of weak fire boiling is 30min-40min;

[0026] Furthermore, in step 3), filtration is performed using gauze; sterilization is performed using high-pressure steam sterilization.

[0027] A second aspect of the present invention provides a product comprising golden lotus extract and loganin; wherein the mass ratio of golden lotus extract to loganin is (5-10):1; the product is used for the treatment and / or prevention of enteritis in animals.

[0028] Furthermore, the product includes any one of the following:

[0029] 1) Medications for the treatment and / or prevention of enteritis in animals;

[0030] 2) Feed additives for the prevention of enteritis in animals;

[0031] Furthermore, the drug also includes a medically acceptable carrier; the carrier includes at least one of excipients, disintegrants, buffers, and pH adjusters;

[0032] The third aspect of this invention provides a method for preparing a traditional Chinese medicine feed additive for preventing enteritis in animals. The method is to mix lotus extract and loganin at a mass ratio of (5-10):1 to obtain the feed additive.

[0033] Furthermore, during mixing, stir at a speed of 300rpm-500rpm to homogenize.

[0034] As can be seen from the above technical solution, the technical effects achieved by this invention are as follows: This invention has discovered that both golden lotus extract and loganin have therapeutic effects on enteritis. Moreover, when the two are used together, compared with the use of a single sample, they can better reduce the level of inflammatory factors in the intestine, verifying the synergistic effect of the two. At the same time, it is precisely because of the synergistic effect of these two substances that golden lotus extract and loganin can be added to feed when raising rabbits and other animals to improve the survival rate of rabbits, provide a guarantee for large-scale meat rabbit breeding enterprises to practice "green breeding and healthy breeding", reduce the incidence of diseases in meat rabbits, and improve the efficiency of breeding enterprises. Attached Figure Description

[0035] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on the provided drawings without creative effort.

[0036] Appendix Figure 1 The fecal condition of rabbits in the negative control group, model group, and prevention group.

[0037] Figure 2 shows the body weight changes of the rabbits in the negative control group, the model group, and the prevention groups. Figure 2 Figure 3 shows the food intake of the rabbits in the negative control group, the model group, and the prevention groups.

[0038] Figure 4 shows the HE staining results of the jejunum mucosa of the rabbits in the negative control group, the model group, and the prevention groups. Figure 3 Figure 5 shows the HE staining results of the ileum mucosa of the rabbits in the negative control group, the model group, and the prevention groups.

[0039] Figure 4 Figure 6 shows the ELISA serum factor detection results of the rabbits in the negative control group, the model group, and the prevention groups.

[0040] Figure 7 shows the intestinal conditions of the rabbits in the negative control group, the model group, and the prevention groups. Figure 5 Figure 8 shows the expression of inflammatory factors in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0041] Figure 6 Figure 9 shows the expression of inflammatory factors in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0042] Figure 10 shows the expression of inflammatory-related genes in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups. Figure 7 Figure 11 shows the expression of inflammatory factors in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0043] Figure 8 Figure 12 shows the expression of inflammatory factors in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0044] Figure 13 shows the expression of inflammatory-related genes in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups. Figure 9 Figure 14 shows the expression of inflammatory factors in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0045] Figure 10 Figure 15 shows the expression of inflammatory-related genes in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0046] Figure 16 shows the expression of inflammatory factors in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups. Figure 11 Figure 17 shows the expression of inflammatory factors in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0047] Figure 12 Figure 18 shows the expression of inflammatory-related genes in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups.

[0048] Figure 19 shows the expression of inflammatory-related genes in the jejunum and ileum of the rabbits in the negative control group, the model group, and the prevention groups. Figure 13 DETAILED DESCRIPTION

[0049] ​​​​​​Clearly, the described embodiments are only a part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those of ordinary skill in the art without creative labor fall within the scope of protection of the present application.

[0050] Currently, there is no technical scheme for applying the extract of Trollius chinensis and loganin to treat animal enteritis in the prior art, and the synergistic effect of the two has not been verified; based on the above defects, the present application provides the use of the combination of the extract of Trollius chinensis and loganin, which includes any one of the following:

[0051] 1) the use in preparing a medicine for treating and / or preventing animal enteritis;

[0052] 2) the use in preparing a feed additive for preventing animal enteritis;

[0053] The structural formula of loganin is shown as formula I.

[0054] I

[0055] .

[0056] The present application adopts the above technical scheme, and the extract of Trollius chinensis and loganin are combined to greatly improve the effect of treating enteritis, which indicates that the extract of Trollius chinensis and loganin have a synergistic effect, and lays a theoretical foundation for treating animal enteritis in clinical animal medicine.

[0057] In some embodiments, the mass ratio of the extract of Trollius chinensis and loganin is (5-10): 1; for example, the mass ratio of the extract of Trollius chinensis and loganin is 5:1, 8:1, or 10:1.

[0058] The present application adopts the above technical scheme, and the mass ratio of the extract of Trollius chinensis and loganin is controlled to be (3-5): 1, so that the effect of treating enteritis is best.

[0059] In some embodiments, the combination of the extract of Trollius chinensis and loganin treats and / or prevents enteritis by any one of the following methods:

[0060] 1) increasing the expression amount of intestinal tight junction protein Claudin-1;

[0061] 2) reducing the levels of inflammatory factors TNF-α and IL-1β in the jejunum and ileum.

[0062] The present application adopts the above technical scheme, and the present application explores the signal pathway and target gene site of the extract of Trollius chinensis and loganin, so as to facilitate the development of targeted drugs.

[0063] In some embodiments, the preparation process of the Potentilla discolor extract is as follows:

[0064] 1) wash the decocting pot and Potentilla discolor with clean water, and then soak them with water;

[0065] 2) add water to the soaked Potentilla discolor, and boil with strong fire, and then adjust to gentle fire;

[0066] 3) filter, sterilize, and decoct twice to obtain the Potentilla discolor extract.

[0067] In some embodiments, the soaking time of water in step 1) is 3h-5h; for example, the soaking time can be 3h, 4h, 5h, or any range value composed of point values; preferably, 4h-5h.

[0068] Compared with the prior art, soaking Potentilla discolor with water can increase the effective components in the decocting liquid; when the soaking time is 3h-5h, the Potentilla discolor can be fully soaked, and the content of the effective components can be maximized.

[0069] In some embodiments, in step 2), when water is added to the soaked Potentilla discolor, the water level needs to be 2-3cm higher than the surface of the medicinal materials.

[0070] In some embodiments, the gentle fire cooking time is 30min-40min; for example, the time can be selected as 30min, 35min, 40min, or any range value composed of point values; preferably, 35min-40min.

[0071] In some embodiments, in step 3), the filtering is with gauze; and the sterilization is high-pressure steam sterilization.

[0072] The second aspect of the embodiments of the present application provides a product comprising a Potentilla discolor extract and loganin; and the mass ratio of the Potentilla discolor extract and the loganin is (15-20):1; the product is used for treating and / or preventing animal enteritis.

[0073] In some embodiments, the product comprises any one of the following:

[0074] 1) a medicine for treating and / or preventing animal enteritis;

[0075] 2) a feed additive for preventing animal enteritis;

[0076] In some embodiments, the medicine further comprises a medically acceptable carrier; the carrier comprises at least one of an excipient, a disintegrant, a buffer, and a pH regulator.

[0077] In some embodiments, the functional food comprises a health product.

[0078] The third aspect of the embodiment of the present application provides a preparation method of the Chinese herbal medicine feed additive for preventing enteritis of animals, which is applied to the preparation of the feed additive, and the preparation method is mixing lotus extract and loganin according to a mass ratio of 5-10:1 to obtain the feed additive. For example, the mass ratio of the lotus extract and the loganin is 5:1, 8:1 or 10:1.

[0079] In some embodiments, when mixing, stirring is performed at a rotating speed of 300 rpm-500 rpm, and homogenization is performed. For example, the rotating speed can be selected as 300 rpm, 400 rpm, 500 rpm or a range value composed of any point value; preferably, the rotating speed is 400 rpm-500 rpm.

[0080] In order to more clearly understand the technical solutions of the present application, the following examples are provided, and it should be understood that, unless otherwise specified, the raw materials used in the examples are commercially available products.

[0081] Example 1: Preparation of lotus extract

[0082] 1) 40 g of lotus was taken, and the lotus was washed with clean water in a decoction pot, and then soaked in water for 3 h;

[0083] 2) water was added to the soaked lotus, and the water level was required to be 2 cm higher than the surface of the medicinal material, and boiled for 15 min with strong fire, and then boiled for 30 min with weak fire;

[0084] 3) filtering with gauze, and then sterilizing with high-pressure steam; water was poured into the remaining dregs, and the water level was required to be 2 cm higher than the surface of the medicinal material, and boiled for 15 min with strong fire, and then boiled for 30 min with weak fire; filtering with gauze, and then sterilizing with high-pressure steam; combining the two filtrates to obtain the lotus extract.

[0085] Example 2: Different from example 1, soaking in water for 5 h, the water level is 3 cm higher than the surface of the medicinal material, and boiling for 40 min with weak fire.

[0086] Example 3: Different from example 1, soaking in water for 4 h, the water level is 2.5 cm higher than the surface of the medicinal material, and boiling for 35 min with weak fire.

[0087] Example 4: Efficacy verification of lotus extract

[0088] 15 36-day-old baby rabbits (female) were taken from the animal room and adapted for 5 days. During this period, the animals were fed with ordinary feed and pure water, and the animals were free to eat and drink water; then 9 baby rabbits were selected and divided into 3 groups, namely a negative control group, a model group and a prevention group, and each group was treated as follows:

[0089] The negative control group: from the 6th day to the 20th day, the basic daily ration was continuously fed, and each rabbit was injected with 100 ml of living water into the abdominal cavity for 15 days.

[0090] Model group: from the 6th to the 20th day, continue to feed the basic diet, 15 days in a row, 200 μg / kg of LPS injection amount is injected intraperitoneally to each one per day on the 16th and 17th day;

[0091] Prevention group: from the 6th to the 20th day, continue to feed the basic diet, while each one drinks 100 ml of the extract of Gypsophila oldhamiana each day, 15 days in a row, 200 μg / kg of LPS injection amount is injected intraperitoneally to each one per day on the 16th and 17th day.

[0092] From the 0th day, the daily feed intake, body weight, fecal condition and mental state of the rabbits are recorded, and the clinical symptoms, mental state, feed intake and fecal condition of the rabbits in each group are observed and recorded every day after LPS injection, and sampling is performed 6 hours after the second injection, 5 ml of blood is taken from the heart, and serum is separated. The daily body weight and feed intake of the rabbits are recorded after the start of feeding the extract of Gypsophila oldhamiana.

[0093] The results are shown in Figure 1 After the 5-day adaptive feeding of the kits, the kits are treated with the extract of Gypsophila oldhamiana for 15 days, and LPS is injected intraperitoneally for 2 days, and the negative control group does not have the clinical symptoms of diarrhea, while the model group and the prevention group have the clinical symptoms of depression and soft feces, and the hair around the anus is not clean.

[0094] After administration, the kits are weighed every day, and the feed intake is counted. The body weight change is shown in Figure 2 , and the feed intake is shown in Figure 3 . The body weight change rate and the feed intake results show that the body weight change and the feed intake of the preventive administration group are basically the same as those of the negative control group. After injection of LPS, the body weight and the feed intake of the model group and the preventive administration group show a significant downward trend.

[0095] The HE staining results of the jejunum and ileum of different groups are shown in Figure 4 and Figure 5 ; the ELISA serum factor detection results are shown in Figure 6 ; it can be seen from Figure 4 that the low-power and high-power microscopes of the negative control group show complete mucosa structure, and no significant abnormalities are observed. The local intestinal villi of the model group are broken, the structure is damaged, and they fall off into the intestinal cavity, and inflammatory cells mainly composed of lymphocytes are observed in the intestinal cavity. The intestinal mucosa structure of the prevention group is complete, and the intestinal villus epithelial cells are slightly proliferated.

[0096] From Figure 5It can be seen that the low-power and high-power microscope of the negative control group can see the complete mucosa structure, and no significant abnormalities are found. The model group: high-power microscope can see intestinal villi necrosis, structure disappearance. A large number of macrophages and lymphocytes can be seen in the lumen. The prevention group: local lamina propria gland hyperplasia, number increase, intestinal villi structure is complete, no significant abnormalities are found. The pathological examination results show that the jejunum sample, the blank control group jejunum structure is complete, no significant abnormalities are found. The model group can see intestinal villi rupture, structure damage, shedding to the lumen, and inflammatory cells mainly composed of lymphocytes can be seen in the lumen. The drug treatment group, the jejunum mucosa structure is complete, and the intestinal villi epithelial cells are slightly hyperplastic, which shows that in the LPS-induced rabbit intestinal inflammation model, the jejunum shows mild intestinal villi structure damage and inflammatory cell infiltration. The drug prevention can reduce the inflammatory response of the jejunum.

[0097] The blank control group jejunum structure is complete, and no significant abnormalities are found. The model group can see intestinal villi necrosis, structure disappearance. A large number of macrophages and lymphocytes can be seen in the lumen. The drug treatment group, the ileum can see the intestinal villi structure is complete, and the local lamina propria gland hyperplasia, number increase. It shows that in the LPS-induced rabbit intestinal inflammation model, compared with the jejunum, the ileum shows more serious intestinal villi necrosis, rupture and shedding, accompanied by macrophages (function is phagocytosis of necrotic cells) and lymphocytes. The drug prevention group, the ileum villi structure is complete, and only the number of glands is hyperplastic (intestinal villi self-repair function).

[0098] Rabbit intestinal qPCR detection

[0099] Sample processing: according to 200ug / kg continuous injection of LPS for two days, 6h after the second injection, the rabbit is killed by air embolism method, and the intestinal tract of each group is observed, see Figure 7 Compared with the normal group, the jejunum of the model group is obviously congested and red, and the cecal intestinal wall is thin, while the intestinal tract of the preventive treatment group shows no obvious change.

[0100] Then separate the duodenum, jejunum, ileum and cecum 3cm sections, and do not do any treatment. The jejunum and ileum segments are gently washed with 4℃ physiological saline for three times, cut into 1cm small segments, and the intestinal inflammation factor level and intestinal tight junction protein Cla expression are detected by RT-PCR method, the steps are as follows:

[0101] RNA extraction

[0102] 1) After adding 500ul PBS and grinding beads in the tissue, grind, take 200ul grinding liquid in a new test tube, add Trizol 1ml to 200ul grinding liquid, and stand at room temperature for 5 min for complete lysis;

[0103] 2) Add 200 μL chloroform (trichloromethane) in EP tube, vortex vigorously for 30 s, and stand at room temperature for 3 min, 4°C, 12000 rpm, centrifuge for 10 min;

[0104] 3) Carefully pipette the supernatant water phase into a new EP tube (do not pipette the middle interface-chloroform layer);

[0105] 4) Add 1 / 2 volume of anhydrous ethanol, mix gently, and add the above solution to the collection column, stand at room temperature for 2 min, 12000 rpm, 4°C, centrifuge for 3 min;

[0106] 5) Discard the supernatant, add 500 μL of RPE, stand at room temperature for 2 min, 12000 rpm, 4°C, centrifuge for 3 min;

[0107] 6) Repeat step 5;

[0108] 7) Discard the supernatant, stand for 2 min, and stand at room temperature for 2 min;

[0109] 8) Add 38 μL DEPC water, stand at room temperature for 5 min, 12000 rpm, 4°C, centrifuge for 3 min;

[0110] 9) Measure the RNA concentration by Nanodrop and store at -80°C.

[0111] RNA reverse transcription

[0112] Quantify the above obtained RNA to 1000 ng, and perform reverse transcription according to the Genestar kit to obtain cDNA. The specific system and procedure are shown in Table 1 below:

[0113] Table 1

[0114]

[0115] Relative quantification of inflammatory factors

[0116] The expression levels of TNF-α, IL-1β, and Cla genes were detected by qRT-PCR. The inflammatory factor gene primers were synthesized by Shanghai Engsing Biotech Co., Ltd., and the primer sequences are shown in Table 2 below;

[0117] Table 2

[0118]

[0119] The cDNA was used as a template, and the target gene was amplified by using GoTaq® qPCR Master Mix kit. According to the standard curve of the pEASY-Blunt-simple-N plasmid construction, the viral copy number was calculated. The qRT-PCR reaction system is shown in Table 3.

[0120] Table 3

[0121]

[0122] The qRT-PCR reaction program was set as follows: 95 ℃, 10 min; 95 ℃, 10 s; 60 ℃, 10 s; 72 ℃, 1 min; 40 cycles.

[0123] The results are shown in Figure 8 and Figure 9 , Figure 10 ; it can be seen from Figure 8 and Figure 9 that after the baby rabbits were sacrificed, the results of the jejunum and ileum inflammatory factors showed that compared with the model group, the TNF-α and IL-1β of the jejunum and ileum of the normal group and the preventive administration group showed a significant downward trend; it can be seen from Figure 9 the results of the tight junction protein Claudin-1 of the jejunum and ileum that after the baby rabbits were sacrificed, compared with the model group, the Claudin-1 of the jejunum and ileum of the preventive administration group showed a significant upward trend; combined with Figure 7 , Figure 8 , Figure 9 , Figure 10 , it can be seen that the extract of Potentilla Flos can reduce intestinal inflammatory factors and reduce the expression of Claudin-1 protein expression gene related to intestinal inflammation, which indicates that the extract of Potentilla Flos has the effect of treating intestinal inflammation.

[0124] Example 5: Synergistic effect of Potentilla Flos extract and Loganin

[0125] The remaining 27 baby rabbits in Example 4 were selected and divided into 9 groups, namely preventive group 1, preventive group 2, preventive group 3, preventive group 4, preventive group 5, preventive group 6, preventive group 7, negative control group, model group, and each group was treated as follows:

[0126] The negative control group: from the 6th day to the 20th day, the basic diet was continued to be fed, and 100 ml of saline was injected intraperitoneally every day for 15 consecutive days;

[0127] The model group: from the 1st day to the 15th day, the basic diet was continued to be fed, and the LPS injection amount was 200 μg / kg per day per rabbit on the 16th and 17th days;

[0128] Prevention group 1: from the 1st day to the 15th day, continue to feed the basic diet, while each rabbit drinks 100ml of gold lotus extract and 5g of loganin per day, for 15 consecutive days, and on the 16th and 17th days, each rabbit is injected with LPS at a dose of 200μg / kg per day by intraperitoneal injection;

[0129] Prevention group 2: from the 1st day to the 15th day, continue to feed the basic diet, while each rabbit drinks 100ml of gold lotus extract and 6g of loganin per day, for 15 consecutive days, and on the 16th and 17th days, each rabbit is injected with LPS at a dose of 200μg / kg per day by intraperitoneal injection;

[0130] Prevention group 3: from the 1st day to the 15th day, continue to feed the basic diet, while each rabbit is fed 12.5g of loganin per day, for 15 consecutive days, and on the 16th and 17th days, each rabbit is injected with LPS at a dose of 200μg / kg per day by intraperitoneal injection.

[0131] The expression of intestinal inflammatory factors and Cla genes in each group of rabbits was counted, and the results are shown in Table 1. Figure 11 and Figure 12 、 Figure 13 .

[0132] Each of the embodiments in the specification is described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the embodiments can be referred to each other.

[0133] The above description of the disclosed embodiments enables a person skilled in the art to implement or use the present application. Various modifications to the embodiments will be apparent to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to the embodiments shown herein, but will conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Use of a combination of a Centaurea extract and an aristolochic acid, characterized in that, The use includes any one of the following: 1) use in the preparation of a drug for treating and / or preventing enteritis of an animal; 2) use in the preparation of a feed additive for preventing enteritis of an animal; The structural formula of the loganin is shown as formula I; I ； The mass ratio of the Trollius chinensis Bunge extract and the loganin is (5-10):

1.

2. Use according to claim 1, characterized in that, The Trollius chinensis Bunge extract and the loganin combination treats and / or prevents enteritis in any one of the following ways: 1) increasing the expression amount of Claudin-1, a tight junction protein of the intestinal tract; 2) reducing the levels of TNF-α and IL-1β, two inflammatory factors of the jejunum and ileum.

3. Use according to claim 2, characterized in that, The preparation process of the Trollius chinensis Bunge extract is as follows: 1) washing the decocting pot and the Trollius chinensis Bunge with clean water, and then soaking with water; 2) adding water to the soaked Trollius chinensis Bunge, boiling with strong fire, and then adjusting to gentle fire; 3) filtering, sterilizing, and repeatedly decocting twice to obtain the Trollius chinensis Bunge extract.

4. Use according to claim 3, characterized in that, In step 1), the soaking time with water is 3h-5h; and / or, In step 2), when adding water to the soaked Trollius chinensis Bunge, the water level needs to be 2-3cm higher than the surface of the medicinal material; and / or, The time of gentle fire boiling is 30min-40min; and / or, In step 3), the filtering is with gauze; and the sterilizing is with high-pressure steam sterilization.

5. A product characterized by, The product includes the Trollius chinensis Bunge extract and the loganin; and the mass ratio of the Trollius chinensis Bunge extract and the loganin is (5-10):1; the product is used for treating and / or preventing enteritis of an animal.

6. A product according to claim 5, characterised in that The product includes any one of the following: 1) a drug for treating and / or preventing enteritis of an animal; 2) a feed additive for preventing enteritis of an animal.

7. A product according to claim 6, characterised in that The drug further includes a medically acceptable carrier; the carrier includes at least one of an excipient, a disintegrant, a buffer, and a pH regulator.

8. A preparation method of Chinese herbal feed additive for preventing enteritis of animals, applied to the preparation of the feed additive of claim 6, characterized in that, The preparation method is mixing the Trollius chinensis Bunge extract and the loganin according to a mass ratio of (5-10):1 to obtain the feed additive.

9. The production method according to claim 8, characterized by, When mixing, stirring is performed at a rotating speed of 300rpm-500rpm, and homogenization is performed.

Images